CTOs on the Move

CureVac

www.curevac.com

 
CureVac is a global biopharmaceutical company in the field of messenger RNA (mRNA) technology, with more than 20 years of expertise in developing and optimizing this versatile biological molecule for medical purposes. The principle of CureVac`s proprietary technology is the use of optimized mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a broad range of diseases. In July 2020, CureVac entered in a collaboration with GSK to jointly develop new products in prophylactic vaccines for infectious diseases based on CureVac`s second-generation mRNA technology. This collaboration was later extended to the ...
  • Number of Employees: 1K-5K
  • Annual Revenue: > $1 Billion
  • www.curevac.com
  • 250 Summer Street 3rd Floor
    Boston, MA USA 02210
  • Phone: 617.377.4040

Executives

Name Title Contact Details
Patrick Baumhof
 Senior Vice President of Technology Profile
Mariola Fotin-Mleczek
 Chief Technology Officer Profile
Mariola Fotin-Mleczek
 Chief Technology Officer Profile

Similar Companies

Argene SA

Argene SA is a Massapequa, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Speedball Fitness

Speedball Fitness is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Molecular Therapeutics

Molecular Therapeutics, Inc. is a Ann Arbor, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Vysis

Vysis, Inc. is a Downers Grove, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Freeline

Freeline is a clinical-stage, fully integrated, next generation, systemic AAV-based gene therapy company with the ambition of transforming the lives of patients suffering from inherited systemic debilitating diseases. We are headquartered in the UK and we also have operations in Germany and the US. Freeline was founded in 2015 and builds upon the pioneering work by our Clinical and Scientific Advisor and Director, Professor Amit Nathwani, Professor of Haematology at UCL. With our liver-based investigational gene therapy technology, we aim to improve the lives of people with chronic systemic diseases and realise the potential of gene therapy treatments.